ESR2 and prostate cancer: Among these six, HLF, JUN, c-MYC, EGR1, SMAD1, and HIF1A, were also identified as PTEN-controlled TFs (Figure 1C), and four, ESR2, MYB, RELA, and USF1, as prostate cancer-related TFs (Figure S2).